CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Co.'s proprietary platform technology, BAROSTIM®, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System (ANS) which causes heart failure (HF) and other cardiovascular diseases. Co.'s second-generation product, BAROSTIM NEO®, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HF and resistant hypertension. The CVRX stock yearly return is shown above.
The yearly return on the CVRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CVRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|